MEDIA

Latest News

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.

21 April 2022

Revance Therapeutics (RVNC) Announces FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines)

21 April 2022

Revance Receives FDA Acceptance of BLA Resubmission for DaxiboutlinumtoxinA for Glabellar Lines

21 April 2022

FDA Accepts Revance Application for Its Injection To Treat Frown Lines

18 April 2022

How Beauty Innovations Are Approved Here and Abroad – Plus the Global Game Changers Doctors are Buzzing About

15 April 2022

What’s The Deal With DAXI, The Neuromodulator Everyone’s Talking About

08 April 2022

Nashville Post: 2022 NAIOP award winners announced

05 April 2022

Here’s How Deep Products and In-Office Treatments Really Penetrate the Skin

30 March 2022

A Derm Approved Guide To Which In-Office Treatments to Book By Season

18 March 2022

RHA 2, 3, 4 and Redensity – What to know about Revance’s HA Fillers

15 March 2022

4 Brand New Face Filler Options You Should Know About Right Now

26 January 2022

RHA Redensity Filler Improves Perioral Rhytids Up To 52 Weeks

20 January 2022

The FDA approves a new dermal filler to reduce the appearance of wrinkles